“Bimekizumab Clinical Efficacy Responses Translate into Improvements in Patient Outcomes to Week 48 in Patients With Moderate to Severe Hidradenitis Suppurativa: Results from BE HEARD I&II”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s707, https://doi.org/10.25251/fpf9fe87.